OBIO Pre-CAAP Company: HCell Granted Orphan Drug Designation by FDA for Alopecia Areata in Pediatric Population
OBIO Pre-CAAP company HCell Inc., a biotechnology company focusing on Alopecia Areata in the Pediatric Population, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with Alopecia Areata, a devastating hair loss disease.